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Background: Obesity has been linked to many adverse health consequences, including breast cancer. This study
aims to determine adipocytokine and other biological changes in recently diagnosed breast cancer patients before
therapy is started.
Methods: A total of 109 female Saudi subjects [56 newly diagnosed, treatment-naïve, histologically-confirmed
breast cancer cases and 53 age- and BMI-matched controls] were enrolled in this study. Anthropometric data were
collected. Serum insulin, adipocytokines and plasminogen activator inhibitor-1 (PAI-1) concentrations were
measured using a customized multiplex Luminex assay. Hypersensitive C-Reactive Protein (CRP), tumor necrosis
factor-alpha (TNF-α), and angiotensin II (ANG II) were measured using ELISA.
Results: A few days in the diagnosis, breast cancer subjects had significantly higher systolic blood pressure
(p = 0.03), glucose (p = 0.01), triglycerides (p = 0.001), leptin (p = 0.044), resistin (p = 0.04), ANG II (p = 0.02),
TNF-α (p = 0.045), and CRP (p = 0.04) than the controls. On the other hand, HDL (p = 0.01) and adiponectin
(p = 0.02) were significantly lower in cancer subjects than controls. A significant association was found
between elevated triglycerides (TG) and breast cancer [OR (95% CI), 6.1(1.8, 15.6), p = 0.004], as well as
elevated ANG II [OR (95% CI), 5.2(1.2, 14.3), p = 0.03]. On the other hand, aPAI and HDL correlated negatively
with breast cancer [OR (95% CI), 0.076(0.01, 0.34), p = 0.001; 0.30(0.09, 0.95), p 0.04, respectively].
Conclusion: Circulating ANGII and triglycerides were positively associated with early breast cancer. In contrast,
HDL-cholesterol correlated negatively with ANG II and aPAI in these patients. This suggests that patients with
recently diagnosed breast cancer have biochemical changes consistent with an activated stress response and/or
that patients with metabolic syndrome manifestations have a higher risk of developing this disease.
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Overweight and obesity, a global phenomenon, affects
more than 1 billion adults, with 300 million being
clinically obese [1]. Obesity has a major impact on
the risk and prognosis of some of the more common
forms of cancer, but also provides us with one of the
few preventive interventions capable of making a sig-
nificant impact on the cancer problem [2]. Weight
increase and obesity in menopausal females have
been identified as the most important prognostic risk
factors for breast cancer in postmenopausal women
[3]. Several studies have reported that at diagnosis of
breast cancer, obese women exhibit an increase in
lymph-node involvement and a higher propensity to
develop distant metastases [4,5].
Breast cancer is the most commonly occurring female
cancer in the industrialized world. Although early diag-
nosis has contributed to therapeutic success, breast
cancer remains a major female health issue and its inci-
dence is increasing in developing countries [3]. Genetic
predisposition and environmental factors, such as a high
fat diet and alcohol consumption, accompanied with a
sedentary life style had been reported to cause an in-
crease in breast cancer risk [3,6].
Metabolic Syndrome, including obesity and T2DM,
are positively associated with an increased breast cancer
risk [7,8]. These conditions are associated with changes
in several hormonal systems, including insulin, estrogen,
cytokines and growth factors [3]. Recent studies have
linked breast cancer with insulin resistance [9-11]; meta-
bolic syndrome (MetS) [12,13], and altered adipokine
levels [14].
Alteration in adipocytokine production in obese
subjects has been reported in several studies. Studies
have shown that increased leptin and decreased adi-
ponectin levels promote carcinogenesis of the breast
[15-18]. It was also shown that adiponectin has prog-
nostic significance in breast cancer recurrence [10].
In addition, obesity is being increasingly recognized
as a form of systemic subclinical inflammation and,
accordingly, an increased adipose tissue infiltration
by immune cells producing inflammatory substances,
including C-reactive protein (CRP) and tumor necro-
sis factor-alpha (TNF-α), which have a positive im-
pact on the breast cancer development [19-21]. CRP
is positively and negatively correlated with leptin and
adiponectin levels, respectively [22,23]. Independent
effect of CRP and alterations in the levels of both
leptin and adiponectin were altogether accompanied
by an increase in breast cancer risk incidence [24].
This aim of this study was to further examine adipocy-
tokines and other metabolic and immune biomarkers of
metabolic syndrome linked with obesity in patients with
early breast cancer prior to therapy initiation.Methods
A case–control study was conducted by the Biomarkers
Research Program (BRP), College of Science, King Saud
University, Riyadh, Kingdom of Saudi Arabia (KSA).
Ethical approval for the study was granted by the Ethics
Committee of King Khalid Hospital, King Saud University,
Riyadh, Kingdom of Saudi Arabia (KSA). A total of 109
female Saudi subjects, consisting of 56 newly diagnosed,
histologically-confirmed breast cancer with no prior
breast cancer treatment and 53 age- and BMI-matched
controls were enrolled in this study. All of the control
subjects were confirmed free from benign or malignant
breast diseases and women with a personal or family
history of any tumor was excluded. All subjects were
free from acute medical conditions, including infections,
at the time of inclusion. Control samples were matched
according to the age and BMI of cases and were taken
from an existing database from the Biomarkers Research
Program. Written informed consent for the utilization of
serum samples and personal information through a
questionnaire for the purpose of research was obtained
from all subjects.
Anthropometrics
Anthropometric data were collected by a designated
research nurse and physician: Height (to the nearest
0.5 cm), weight (to the nearest 0.1 kg), waist and hip cir-
cumference (measured using a standardized measuring
tape in cm) in addition to systolic and diastolic blood
pressure measurements. Body mass index (BMI) was cal-
culated as kg/m2. WHR was also calculated as waist
divided by hip circumference. Fasting blood samples
from cases were extracted after diagnosis and prior to
breast cancer therapy initiation. Blood was transferred
immediately to a non-heparinized tube for centrifuga-
tion. Serum was then transferred to a pre-labeled plain
tube, stored in ice, and delivered to the Biomarker Re-
search Center in King Saud University on the same day.
Metabolic measurements
Fasting serum samples were stored in a −20°C freezer
prior to analysis. Serum glucose, triglycerides, total
and HDL-cholesterol levels were measured by chemis-
try auto-analyzer (Konelab, Espoo, Finland) and con-
centrations of LDL-cholesterol were calculated using
Friedwald's formula. Determination of serum insulin, lep-
tin, adiponectin, resistin, and aPAI-1 was done using custo-
mized multiplex assay kits that utilize the LuminexW
xMAPW Technology platform (Luminex Corporation,
Texas, USA).
For parameters measured using the multiplex assay,
the intra-assay variation was 1.4-7.9% and inter-assay
variation of < 21%. Minimum detectable concentrations
(MDC) were as follows: insulin 50.9 pg/ml; leptin 85.4
Table 1 General characteristics of subjects
Control Breast cancer P value
N 53 56
Age (years) 43.1 ± 7.5 46.4 ± 11.3 0.10
Age at Menarche (years) 13.1 ± 1.0 12.9 ± 1.6 0.48
Age at 1st Pregnancy (years) 21.0 ± 3.8 19.6 ± 4.3 0.19
Menopause (%) 9 (17) 22 (40) 0.01
Body Mass Index (kg/m2) 31.0 ± 5.4 31.4 ± 7.7 0.81
Systolic BP (mmHg) 112.3 ± 11.98 118.6 ± 15.5 0.03
Diastolic BP (mmHg) 73.3 ± 7.0 70.9 ± 10.5 0.22
SAD (cm) 22.1 ± 5.8 20.2 ± 8.3 0.30
Waist circumference (cm) 88.8 ± 18.8 96.3 ± 22.2 0.08
Hip circumference (cm) 106.5 ± 21.4 105.5 ± 18.2 0.81
Glucose (mmol/l) 5.4 ± 0.63 5.9 ± 1.2 0.01
Triglycerides (mmol/l) 1.3 ± 0.22 1.9 ± 0.38 0.001
Total Cholesterol (mmol/l) 4.7 ± 0.62 4.9 ± 1.0 0.27
LDL-Cholesterol (mmol/l) 3.6 ± 0.76 3.7 ± 1.0 0.51
HDL-Cholesterol (mmol/l) 0.86 ± 0.29 0.72 ± 0.26 0.01
C-Reactive Protein (ug/ml) 4.4 ± 0.11 7.5 ± 0.21 0.04
ANG II (ng/ml) 0.77 ± 0.15 0.99 ± 0.29 0.02
Leptin (ng/ml) 16.0 ± 2.2 25.6 ± 1.7 0.044
Adiponectin (ug/ml) 19.1 ± 1.2 14.8 ± 1.0 0.02
TNF-α (pg/ml) 4.6 ± 0.57 6.0 ± 0.75 0.045
aPAI (ng/ml) 14.6 ± 1.3 12.2 ± 2.8 0.08
Resistin (ng/ml) 15.2 ± 1.0 18.9 ± 1.2 0.04
Ca (mmol/l) 2.4 ± 0.23 2.3 ± 0.58 0.18
Pi (mmol/l) 1.2 ± 0.18 1.6 ± 0.34 <0.001
Note: Data presented as mean ± SD; P-value significant at < 0.05.
Table 2 Menopausal status and Age of menarche
-adjusted Odds-ratio [confidence interval (CI) 95% for
Breast cancer in Relation to Glucose, HDL, Triglycerides,
CRP, ANG II, Adiponectin , Leptin, TNF-a, aPAI, and
Resistin levels
Odds ratio (95% CI) P-Value
Glucose (mmol/l) 2.2 (0.68, 7.1) 0.63
Triglycerides (mmol/) 6.1 (1.8, 15.6) 0.004
HDL-Cholesterol (mmol/l) 0.30 (0.09, 0.95) 0.04
C-Reactive Protein (ug/ml) 2.1 (0.53, 8.1) 0.29
ANG II (ng/ml) 5.3 (1.2, 14.3) 0.03
Leptin (ng/ml) 1.6 (0.33, 7.9) 0.53
Adiponectin (ug/ml) 0.44 (0.12, 1.5) 0.19
Resistin (ng/ml) 1.9 (0.62, 5.7) 0.26
TNF-α (pg/ml) 1.59 (0.44, 5.7) 0.47
aPAI (ng/ml) 0.076 (0.01, 0.34) 0.001
Note: P-value significant at p < 0.05.
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PAI-1 1.3 pg/ml. The rest of the parameters were quanti-
fied using individual enzyme-linked immunosorbent assay
kits (ELISA): CRP (Immunodiagnoztik AG, Germany) with
an intra-assay variability of 5.5-6.0% and inter-assay vari-
ation of 11.6-13.8%; TNF-α (Biosource, Belgium); ANG-II
(R and D Systems, MN).
Statistical analysis
Data analysis was carried out using the Statistical Pack-
age for the Social Sciences (SPSS for Windows, version
16.0). Power calculation was done ascertaining differ-
ences in mean CRP levels between cases and controls. A
total sample size of 88 has 80% power to detect a signifi-
cance at α = 0.03. Data are expressed as mean ± standard
deviation, while medians (inter-quartile range) were
shown for non-normal continuous variables. Independ-
ent student t-test was used to compare group differences
for normal parameters. For non-normal parameters,
Mann–Whitney U-test was utilized. Multinomial logistic
regression analysis was done using the presence of
breast cancer as dependent variable and parameters of
interest as independent variables adjusted for meno-
pause and age of menarche. Partial correlation analysis
was used to determine associations between variables
of interest. Significance was set at p < 0.05. All statis-
tical analyses were conducted using SPSS version 16.5
(Chicago, IL).
Results
Table 1 highlights the general characteristics of our fe-
male subjects. Data revealed that breast cancer subjects
had significantly higher systolic blood pressure (p =
0.03), glucose (p = 0.01), triglycerides (p = 0.001), leptin
(p = 0.044), resistin (p = 0.04), Ang II (p = 0.02), TNF-α
(p = 0.045), and CRP (p = 0.04) than controls. On the
other hand, HDL (p = 0.01) and adiponectin (p = 0.02)
were significantly lower in breast cancer subjects than
controls. The rest of the comparisons were non-
contributory.
Table 2 shows odds ratios for breast cancer in relation
to glucose, HDL, triglycerides, CRP, ANG II, adiponectin,
leptin, TNF-α, aPAI, and resistin levels. A significant as-
sociation was found between elevated levels of triglycer-
ides and risk of breast cancer [OR (95% CI), 6.1 (1.8,
15.6), p = 0.004]. Significant associations were also found
between elevated levels of ANG II and risk of developing
breast cancer in females [OR (95% CI), 5.3 (1.2, 14.3),
p = 0.03]. On the other hand aPAI and HDL had a pro-
tective effect with the risk of developing breast cancer
[OR (95% CI), 0.076 (0.01, 0.34), p = 0.001; 0.30 (0.09,
0.95), p = 0.04, respectively].
Linear regression analyses using CRP, ANG II, adipo-
nectin, leptin, TNF-α, aPAI, and resistin as dependent
Table 3 Correlation analysis using CRP, ANG II, Adiponectin, Leptin, TNF-α, aPAI and Resistin as dependent variables in
all subjects, controls and cases
















BMI (kg/m2) 0.38**; NS; 0.52** 0.32**; NS; 0.44**
Systolic BP (mmHg) NS; NS; 0.36*
Diastolic BP (mmHg) 0.25*; NS; NS
SAD (cm)
Waist (cm) 0.44**; NS; 0.48** 0.23*; NS; NS −0.35**; NS; -0.45**
Hips (cm) NS; NS; 0.35* 0.25*; NS; 0.44*










NS; 0.38*; NS −0.29**;-0.31*;
CRP (ug/ml) 0.26*; NS; 0.40* −0.27*; -0.32*; NS −0.26*; NS; -0.32*
ANG II (ng/ml) NS; 0.48**; NS
Leptin (ng/ml) 0.26*; NS; 0.41* 0.23*; NS; NS
Adiponectin (ug/ml) −0.27*; NS; NS NS; 0.28*; NS NS; 0.34*; NS
Resistin (ng/ml) −0.26*; NS; -0.32* NS; 0.45**; NS
TNF-α (pg/ml) 0.23*; 0.34*; NS; NS; -0.38* 0.44**; 0.45**; 0.58**
aPAI (ng/ml) NS; 0.48*; NS NS; 0.37**; NS 0.44**; 0.45**;
0.58**
Ca (mmol/l) −0.61**; NS; -0.75**
Pi (mmol/l) 0.36**; NS; NS
Note: Only significant associations were presented; Values presented as coefficient R; Coefficients presented from left to right [All, Control, Cases]; NS – Not
Significant; * denotes significance at < 0.05 level; 88 denotes significance at < 0.001 level.
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Table 3. Data showed that CRP was positively associated
with BMI (r = 0.38, p = 0.001), waist (r = 0.44, p > 0.001),
leptin (r = 0.44, p > 0.001) and negatively associated with
adiponectin (r = −0.27, p = 0.02) and resistin (r = −0.26,
p = 0.02). Adiponectin was negatively associated with
waist (r = −0.35, p = 0.001), triglycerides (r = −0.26, p =
0.01), and CRP (r = −0.27, p = 0.02) and positively asso-
ciated with HDL (r = 0.23, p = 0.03). Leptin was positively
associated with BMI (r = 0.32, p = 0.006), waist (r = 0.23,
p = 0.05), hips (r = 0.25, p = 0.04), CRP (r = 0.26, p = 0.04),
and TNF-α (r = 0.23, p = 0.05). TNF-α was positively
associated with triglycerides (r = 0.26, p = 0.01), leptin
(r = 0.23, p = 0.05), aPAI-1 (r = 0.44, p < 001). aPAI-1 was
positively associated with diastolic BP (r = 0.25, p =
0.03), glucose (r = 0.28, p = 0.01), and TNF-α (r = 0.44,
p < 0.001) and negatively associated with cholesterol
(r = −0.28, p = 0.02), LDL (r = −0.29, p = 0.008) and
calcium (r = −0.61, p < 0.001). Resistin was positivelyassociated with calcium (r = 0.36, p = 0.01) and nega-
tively associated with CRP (r = −0.26, p = 0.02).
Discussion
Obesity is an established risk factor for most hormone-
dependent cancers, including breast cancer. The path-
ology underlying this phenomenon may be related to the
endocrine and metabolic profile of this state. In the
present case–control study, our results indicate that
metabolic changes among newly diagnosed breast cancer
patients are consistent with a systemic stress response,
possibly because of the presence and/or diagnosis of
cancer activating the stress-system that, in turn, alters
further the existing metabolic state to an environment
conducive to tumor growth. It has been well established
that stress, both acute and chronic induces a powerful
cascade of immune, metabolic and inflammatory reac-
tions [25]. On the other hand, we cannot exclude preex-
isting metabolic syndrome manifestations as a risk factor
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nations are not mutually exclusive.
Our current data suggest that there is a positive associ-
ation between triglycerides and ANG II levels in patients
newly diagnosed with breast cancer. ANG II is a biologic-
ally active peptide of the renin-angiotensin system (RAS)
involved in blood pressure regulation, tissue remodeling
and angiogenesis, as well as in vascular and inflammatory
pathologies. Consequently, the major functions attributed
to ANG II (inflammation, angiogenesis and migration) are
also related to cancer progression [26-28]. We also showed
that there is a negative association of ANG II with HDL
and aPAI which were in agreement with previous studies
[29,30]. However, other studies reported a positive associ-
ation between ANG II and breast cancer [31,32]. On the
other hand, a very recent study involving more than
230,000 women (Swedish AMORIS Study) showed no as-
sociation between HDL and breast cancer risk, while it
demonstrated a weak protective association between circu-
lating triglycerides and risk for breast cancer [33].
Obesity is increasingly associated with postmenopausal
breast cancer risk [34], whereas, in premenopausal
women there is an inverse relation between BMI and
breast cancer risk [35,36]. We have previously demon-
strated in our cross-sectional study that inflammatory
biomarkers known to be elevated in breast cancer
patients (IL-6 and CRP) are also increased in obese and
insulin resistant pre-menopausal women [37]. The
present findings, therefore, confirm that inflammatory
markers, specifically CRP and TNF-α are elevated in
newly diagnosed patients with breast cancer.
Inflammation is associated with poor prognosis and
decreased survival in many cancers. As obesity per se is
considered a subclinical inflammation, the increased
levels of TNF-α and CRP in breast cancer cases in the
present study are consistent with stress-induced inflam-
mation among newly diagnosed breast cancer patients.
In addition, CRP was positively correlated with BMI and
inversely with adiponectin levels, in agreement with previ-
ous reports [22,23]. Thus, in obesity, the adipocytokines
and in particular, adiponectin and the inflammatory media-
tors might exert an additive effect to positively impact
breast cancer pathogenesis.
Our data showed significantly elevated mean level of
serum glucose, diastolic blood pressure and reduced
HDL in the breast cancer group. Previous studies
reported that high fasting glucose levels were directly
correlated with breast cancer both in pre-menopausal
and postmenopausal women [38,39]. In addition,
reduced HDL-cholesterol and increased blood pressure
contributed to increased risk for breast cancer [40,41].
Furthermore, low HDL-cholesterol, hypertension, and
hyperglycemia have all been associated with breast can-
cer [38,40,42-44].The authors acknowledge some limitations. The case–
control cross-sectional design limits the findings to at
best, suggestive. The small sample size might explain the
failure to produce significant associations in parameters
that were expected to associate with clinical variables.
Furthermore several confounders were excluded such as
family history of breast cancer and medications and as
such the findings cannot be generalized. Despite these
limitations, the present study is among the few to ob-
serve pathologic changes in the adipocytokine, metabolic
and immune biomarkers among early diagnosed breast
cancer patients. These changes may reflect an earlier risk
or a stressful environment conducive to tumor growth
and/or both.Conclusions
In conclusion, inflammatory and metabolic changes are
apparent among patients with early breast cancer as evi-
denced by the strong positive link between CRP and
BMI, the positive association between ANG II and trigly-
cerides, the negative association between HDL and adi-
ponectin, and the strong negative association between
PAI-1 and HDL. These associations, independent of age
and BMI, are consistent with stress-induced changes
secondary to the early breast cancer and/or the psycho-
logic impact of the diagnosis, might enhance tumori-
genic activity and lead to a poorer prognosis if left
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